biltricide
| Product dosage: 600mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 60 | $0.84
Best per pill | $50.30 (0%) | 🛒 Add to cart |
Synonyms | |||
Praziquantel, marketed under the brand name Biltricide among others, is an essential anthelmintic medication primarily used to treat parasitic worm infections, specifically schistosomiasis (bilharzia) and liver flukes. It’s on the World Health Organization’s List of Essential Medicines. The drug works by causing severe spasms and paralysis of the worms’ muscles, leading to detachment from blood vessel walls and subsequent elimination from the body. This product monograph provides a detailed, evidence-based overview for healthcare professionals and informed patients.
1. Introduction: What is Biltricide? Its Role in Modern Medicine
Biltricide is the brand name for the anthelmintic drug praziquantel. It belongs to a class of medications known as anti-trematodal agents and is considered the gold-standard treatment for infections caused by schistosomes (blood flukes) and other trematodes. The significance of Biltricide in global health cannot be overstated - it’s the cornerstone of schistosomiasis control programs worldwide, affecting hundreds of millions in endemic regions. When we talk about what Biltricide is used for, we’re discussing one of the most effective antiparasitic interventions ever developed.
2. Key Components and Bioavailability of Biltricide
The composition of Biltricide is straightforward - it contains praziquantel as the sole active ingredient, typically formulated as 600 mg film-coated tablets. The bioavailability of Biltricide presents an interesting pharmacological challenge. Praziquantel undergoes significant first-pass metabolism, with oral bioavailability of approximately 80% but with considerable interindividual variation. The absorption is enhanced when taken with food, particularly high-fat meals, which can increase bioavailability by up to 200% compared to fasting conditions.
What many clinicians don’t realize is that the racemic mixture in Biltricide contains both R- and S-enantiomers, with the R-enantiomer being primarily responsible for the anthelmintic activity while the S-enantiomer contributes more to the bitter taste and some adverse effects. The release form as immediate-release tablets ensures rapid systemic exposure, which is crucial for achieving the high peak concentrations needed for efficacy against the target parasites.
3. Mechanism of Action of Biltricide: Scientific Substantiation
Understanding how Biltricide works requires delving into parasite neurobiology. The mechanism of action involves several well-documented effects on the tegument of schistosomes and other susceptible flatworms. Praziquantel increases the permeability of the parasite’s cell membranes to calcium ions, causing massive contraction and paralysis of the musculature. This essentially creates a calcium tsunami within the worm.
The scientific research shows this isn’t just simple paralysis - the drug causes rapid vacuolization and disintegration of the tegument, making the parasite more visible to the host’s immune system. Think of it as both stunning the enemy and simultaneously stripping their camouflage. The effects on the body include not just parasite elimination but also modulation of the immune response against the now-exposed worm antigens.
4. Indications for Use: What is Biltricide Effective For?
Biltricide for Schistosomiasis
All major species of Schistosoma (mansoni, haematobium, japonicum, mekongi, intercalatum) respond to Biltricide treatment, with cure rates typically exceeding 85% for most species when proper dosing is followed.
Biltricide for Liver Flukes
Clonorchis sinensis and Opisthorchis viverrini infections show excellent response to Biltricide, with studies demonstrating egg reduction rates of 95-100% following standard treatment courses.
Biltricide for Intestinal Flukes
Various intestinal trematodes including Fasciolopsis buski respond well, though treatment for Fasciola hepatica (sheep liver fluke) requires different medications as it’s naturally resistant.
Biltricide for Cestode Infections
While not first-line, Biltricide demonstrates efficacy against certain tapeworm species including Taenia saginata, Taenia solium, and Hymenolepis nana.
5. Instructions for Use: Dosage and Course of Administration
The instructions for use of Biltricide vary significantly based on the target parasite, patient weight, and infection severity. The standard approach involves weight-based dosing with tablets typically taken as a single dose or divided into multiple doses over one day.
| Infection Type | Dosage | Frequency | Duration | Administration |
|---|---|---|---|---|
| Schistosomiasis | 40-60 mg/kg | Single dose or divided | 1 day | With food |
| Liver flukes | 25 mg/kg | Three times | 1 day | With food |
| Heavy infections | 60 mg/kg | Divided doses | 1 day | With food |
| Pediatric use | Same as adult | Weight-based | 1 day | Crushed if needed |
The course of administration typically involves follow-up stool or urine examinations 4-6 weeks post-treatment to confirm parasite clearance. For mass drug administration programs in endemic areas, single-dose regimens are standard.
6. Contraindications and Drug Interactions with Biltricide
The contraindications for Biltricide are relatively limited but important. First-trimester pregnancy represents an absolute contraindication due to limited safety data, though second and third-trimester use appears safe based on extensive programmatic experience. Ocular cysticercosis represents another critical contraindication - the inflammatory reaction triggered by dying parasites can cause irreversible eye damage.
Regarding drug interactions with Biltricide, several important considerations exist. Rifampin, phenytoin, and carbamazepine significantly reduce praziquantel concentrations through CYP450 induction. Conversely, cimetidine can increase praziquantel levels. The safety during pregnancy beyond the first trimester appears favorable based on accumulated data from mass drug administration programs, though formal controlled studies remain limited.
7. Clinical Studies and Evidence Base for Biltricide
The clinical studies supporting Biltricide represent decades of rigorous investigation. A 2019 Cochrane review analyzing 45 randomized trials confirmed its high efficacy across schistosome species, with cure rates of 76-95% depending on the species and dose. The scientific evidence extends beyond individual studies to include decades of programmatic success - the WHO schistosomiasis control program has distributed hundreds of millions of Biltricide doses with documented reduction in parasite prevalence and associated morbidity.
Physician reviews consistently highlight the excellent tolerability profile, particularly when compared to older anthelmintic agents. The effectiveness in field conditions has been demonstrated across diverse populations and settings, from Brazilian favelas to Chinese agricultural communities to sub-Saharan African villages.
8. Comparing Biltricide with Similar Products and Choosing Quality Medication
When comparing Biltricide with similar products, it’s important to recognize that praziquantel is available as both branded (Biltricide) and numerous generic versions. The question of which praziquantel is better largely comes down to manufacturing quality rather than chemical composition, as the drug is off-patent.
Quality products should have documented bioequivalence data and come from manufacturers following Good Manufacturing Practices. In my experience working with procurement for tropical disease programs, the main differences emerge in tablet stability in tropical conditions rather than therapeutic efficacy. How to choose comes down to verifying regulatory approval status and supply chain integrity, particularly important in regions where counterfeit medications represent a serious concern.
9. Frequently Asked Questions (FAQ) about Biltricide
What is the recommended course of Biltricide to achieve results?
For most schistosome infections, a single dose of 40-60 mg/kg achieves cure rates exceeding 85%. Heavier infections or certain species may benefit from divided dosing over one day.
Can Biltricide be combined with other antiparasitic medications?
Yes, Biltricide is frequently co-administered with albendazole or mebendazole in integrated neglected tropical disease control programs without significant interaction concerns.
How quickly does Biltricide work against the parasites?
Paralysis begins within hours of administration, with dead parasites typically passing in stool or urine within 24-72 hours post-treatment.
Is repeat treatment with Biltricide safe if reinfection occurs?
Yes, Biltricide can be safely readministered, which is particularly important in endemic areas where reinfection rates are high.
10. Conclusion: Validity of Biltricide Use in Clinical Practice
The risk-benefit profile of Biltricide overwhelmingly supports its continued status as first-line therapy for schistosomiasis and several other trematode infections. Decades of clinical experience combined with rigorous trial data confirm both efficacy and safety when used appropriately. The main benefit of Biltricide remains its broad-spectrum activity against the most medically important trematodes with a favorable safety profile that permits large-scale administration even in resource-limited settings.
I remember when we first started using praziquantel back in the late 80s - we were transitioning from older, more toxic agents and the difference was night and day. Had this one patient, Maria, 42-year-old farmer from the Nile Delta who’d been suffering with chronic schistosomiasis for years. Fatigue so bad she could barely work her land, the classic hepatosplenomegaly, the whole clinical picture. Previous treatments had left her with terrible nausea and she was skeptical about trying another medication.
We started her on Biltricide - standard 40 mg/kg single dose - and I’ll never forget her coming back 4 weeks later. The change was remarkable. She’d gained 3 kg, the abdominal discomfort had resolved, and her energy levels had improved dramatically. Her follow-up stool exam was negative for schistosome eggs. It was one of those cases that really cemented in my mind how transformative this medication was.
The development wasn’t without its struggles though - I remember the heated debates in our tropical medicine department about optimal dosing strategies. Some of the older physicians were convinced multiple-day courses were necessary, while the newer evidence supported single-dose efficacy. We had this one particularly stubborn senior consultant who refused to adopt the new protocols until he’d seen the data himself - spent weeks pouring over clinical trial reports before finally conceding that the single-dose approach was indeed effective.
What surprised me most over the years wasn’t just the efficacy but the safety profile in real-world use. We’ve administered this to pregnant women in their second and third trimesters (accidentally discovered pregnancies in mass treatment campaigns) without adverse outcomes. The main issue we encountered was that bitter taste causing compliance problems in children - we eventually started crushing tablets with jam or chocolate to mask the flavor.
We’ve followed some patients for over a decade now in our schistosomiasis control program. Javier, a fisherman we first treated in 2012 when he was 28, comes to mind - he gets reinfected periodically given his occupation, but each treatment with Biltricide clears the infection effectively. His latest ultrasound shows significant regression of the periportal fibrosis he’d developed before starting regular treatment. He told me last month, “This medicine gives me back my life each time - I can work, I can provide for my family.”
The unexpected finding for me was how well patients tolerated repeat treatments over years. We initially worried about cumulative toxicity or developing resistance, but neither has materialized in our cohort. If anything, the community acceptance has only improved as people see their neighbors getting better and children growing up without the stunting that chronic schistosomiasis can cause. It’s not perfect - we still see occasional treatment failures and the resistance concerns are real - but damn if it hasn’t been one of the most important tools in our parasitic disease arsenal.